MedTrace Logo

Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency

NCT00630708 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 309

Last updated 2016-04-05

No results posted yet for this study

Summary

The primary aim of the present study is to assess the safety of combined treatment of benazepril (an ACE inhibitor) or losartan (an ARB) in non-diabetic patients with advanced renal insufficiency.

Conditions

  • Renal Insufficiency, Chronic

Interventions

DRUG

Benazepril

20 mg per day

DRUG

Losartan

100 mg per day

DRUG

Benazepril+Losartan

combination treatment of 10 mg benazepril and 50 mg losartan per day

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • Fan Fan Hou, M.D.,Ph.D. · Renal Division, Nanfang Hospital,Southern Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00630708 on ClinicalTrials.gov